Latest News - Clinical Trials

Monday, June 19, 2017 | Clinical Trials, BioTime

Biotime Expands & Advances Ophthalmology Portfolio

BioTime reported several developments for its ophthalmology portfolio, including: Signing a new and expanded licensing agreement with Hadassah Medical Organization of Jerusalem, Israel Present…

Read the full story

Wednesday, June 14, 2017 | Clinical Trials, GenSight Biologics

GenSight Biologics Reports Long-Term Results in Phase 1/2 Study of GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy

GenSight Biologics reported additional promising clinical trial results with GS010 after 96 weeks of follow-up in its phase 1/2 study. These results confirm the long-term positive sustained visual acu…

Read the full story

Wednesday, June 14, 2017 | Clinical Trials, Omeros

FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy

Omeros announced that the FDA has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros’ lead human monoclonal antibody tar…

Read the full story

Tuesday, June 13, 2017 | Clinical Trials, Psivida

pSivida’s Durasert 3-year Treatment for Posterior Segment Uveitis Achieves Primary Efficacy Endpoint

A second phase 3 trial of pSivida's Durasert 3-year treatment for posterior segment uveitis achieved the trial’s primary endpoint. The study involved 153 patients and the primary endpoint wa…

Read the full story

Monday, June 12, 2017 | Clinical Trials, Conferences

Verseon to Reveal Preclinical Results on Novel Drug Candidates in Diabetic Macular Edema Program at BIO 2017

Verseon will be presenting results from its most advanced drug programs at the 2017 BIO International Conference, held June 19 -- 22, 2017 in San Diego. Dr. David Kita, Vice President of R&D at Ve…

Read the full story

Sunday, June 04, 2017 | Clinical Trials

Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial

Aldeyra Therapeutics announced that it has enrolled the first patient in a phase 3 clinical trial of topical ocular ADX-102 for the treatment of noninfectious anterior uveitis (NAU). "Based on…

Read the full story

Thursday, June 01, 2017 | Clinical Trials, Avedro

Results From Avedro's Landmark Corneal Collagen Cross-Linking Pivitol Phase 3 Keratoconus Studies Published

Avedro announced the publication of 1-year safety and efficacy data from the randomized, controlled pivotal phase 3 clinical trials that supported the FDA approval of Avedro’s Photrexa Viscous (…

Read the full story

Wednesday, May 31, 2017 | Clinical Trials, Dry Eye

Lamellar Biomedical Recruits First Patients into Clinical Study Assessing Lamelleye for Treatment of Dry Eye Disease

Lamellar Biomedical announced the recruitment of the first patients in a clinical study assessing Lamelleye for the treatment of moderate to severe dry eye disease (DED). Lamelleye is designed to prov…

Read the full story

Wednesday, May 24, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Roclatan

Aerie Pharmaceuticals reported the successful primary efficacy results of the company’s 90-day, phase 3 Mercury 2 registration trial for its fixed-dose combination product candidate, Roclatan. T…

Read the full story

Tuesday, May 23, 2017 | Clinical Trials

Dompé Receives Positive CHMP Opinion in Europe For Oxervate for the Treatment of Adult Patients with Moderate or Severe Neurotrophic Keratitis

Dompé has announced that the Committee for Human Medicinal Products of the European Medicines Agency (EMA) has released a positive opinion, recommending the marketing authorization for Oxervate…

Read the full story

Monday, May 15, 2017 | Clinical Trials, Glaucoma

Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma and Preclinical Data Supportive of AMD/DME Potential at ARVO

Isarna Therapeutics announced the presentation of the phase I safety and efficacy data for its lead candidate ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, in advanced-stage glau…

Read the full story

Monday, May 15, 2017 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa

Aerie Pharmaceuticals reported that it has received notification from the FDA that the agency has completed its initial 60-day review of the Rhopressa new drug application (NDA) and determined that th…

Read the full story

Friday, May 12, 2017 | Clinical Trials

Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor (DENKI) at ARVO

Pharmaleads announced positive efficacy and safety results of PL265, a novel Dual ENKephalinase Inhibitor (DENKI), in a preclinical study for ocular pain. This study was conducted in collaboration wit…

Read the full story

Wednesday, May 10, 2017 | Clinical Trials, BioTime

BioTime Announces New Positive Data from OpRegen Trial in Dry-AMD

BioTime announced new data from the phase 1/2a clinical trial of OpRegen in the advanced form of dry age-related macular degeneration (AMD). The interim data were presented on May 8, 2017 at the …

Read the full story

Wednesday, May 10, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained-Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI)

Ocular Therapeutix presented data from preclinical studies evaluating the efficacy, tolerability, and pharmacokinetics of its sustained-release intravitreal tyrosine kinase inhibitor (TKI) depot (OTX-…

Read the full story
Load More